1. Home
  2. ONL vs ABOS Comparison

ONL vs ABOS Comparison

Compare ONL & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Orion Office REIT Inc.

ONL

Orion Office REIT Inc.

HOLD

Current Price

$2.55

Market Cap

113.2M

Sector

Real Estate

ML Signal

HOLD

Logo Acumen Pharmaceuticals Inc.

ABOS

Acumen Pharmaceuticals Inc.

HOLD

Current Price

$2.39

Market Cap

114.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ONL
ABOS
Founded
2021
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
113.2M
114.5M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
ONL
ABOS
Price
$2.55
$2.39
Analyst Decision
Buy
Strong Buy
Analyst Count
2
4
Target Price
$3.00
$7.50
AVG Volume (30 Days)
322.9K
1.4M
Earning Date
03-05-2026
03-26-2026
Dividend Yield
3.09%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$149,775,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.46
$0.86
52 Week High
$4.25
$3.05

Technical Indicators

Market Signals
Indicator
ONL
ABOS
Relative Strength Index (RSI) 64.28 52.49
Support Level $2.15 $2.33
Resistance Level $2.67 $2.58
Average True Range (ATR) 0.14 0.33
MACD 0.03 -0.01
Stochastic Oscillator 80.99 33.75

Price Performance

Historical Comparison
ONL
ABOS

About ONL Orion Office REIT Inc.

Orion Properties Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.

About ABOS Acumen Pharmaceuticals Inc.

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.

Share on Social Networks: